No Bull's Eye Without a Target

Dr. Mark Kris stresses that EGFR-targeted therapies provide no benefit in lung cancer patients who have no activating mutations, as evidenced in a recent study.
Source: Medscape Pulmonary Medicine Podcast - Category: Respiratory Medicine Authors: Source Type: podcasts